Amgen Parkinson's drug fails in mid-stage trial

06/29/2004 | CNNMoney

Amgen reported the trial failure of an experimental drug intended to treat Parkinson's disease. A mid-stage trial of 34 patients showed the drug, GDNF, did not meet the goal of improving symptoms over six months compared with a placebo, but Amgen said it is studying the data to determine why the study results differ from a three-year study in the U.K. that shows long-term improvements.

View Full Article in:

CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC